Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Surrogate Endpoints Don't Convince ODAC: Panel Votes No On Two Centocor/Ortho Biotech Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

ODAC votes 14-1 against Yondelis in combination with Doxil for ovarian cancer, and 13-0 against Doxil in combination with docetaxel for metastatic breast cancer.
Advertisement

Related Content

Oncology Has Different Risk Management Standards, FDA’s Pazdur Acknowledges
J&J Pulls Yondelis NDA For Ovarian Cancer Ahead Of Final Survival Data Release
J&J Pulls Yondelis NDA For Ovarian Cancer Ahead Of Final Survival Data Release
Two In One Day: Centocor Ortho Biotech Gets Complete Response Letters For Doxil In Breast Cancer And Yondelis In Ovarian Cancer
Second Consecutive Year Of Growth In NME Approvals In The Cards For FDA
Accelerated Approval Does Not Speed Oncologics To Market, Study Finds
ODAC Says Toxicity Trumps Meager PFS And TTP Benefit for Yondelis, Doxil
Ortho Biotech's Yondelis In Ovarian Cancer Test Case For Progression Free Survival Endpoint
Ortho Biotech's Yondelis In Ovarian Cancer Test Case For Progression Free Survival Endpoint
Second Consecutive Year Of Growth In NME Approvals In The Cards For FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS069703

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel